Literature DB >> 16583225

[Rational symptomatic therapy for chronic pruritus].

S Ständer1.   

Abstract

Chronic pruritus is a difficult-to-treat problem which accompanies many dermatologic and systemic diseases. Frequently, therapy is ineffective and prolongs the pruritus. Thus significant costs arise for the health system, which are clearly lowered by a rational therapy concept. Extensive knowledge about both topical and systemic therapy of pruritus has been acquired in recent years. Currently, new therapeutic approaches are available, which intervene in different pruritogenic mechanisms. Substances can block the cutaneous pruritus induction (e.g. antihistamines, leukotriene antagonists, cannabinoid agonists) or mediate central effects such as the inhibition of pruritus transmission via the spinal cord (e.g. naltrexone, gabapentin) or the suppression of the cerebral itch perception (e.g. antidepressants, neuroleptics). Usually combining several therapeutic principles is necessary in order to suppress chronic pruritus with lasting effect. The most effective approach is to gradually combine therapies, always considering both the medical and financial impacts.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16583225     DOI: 10.1007/s00105-006-1123-x

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  20 in total

1.  Treatment of prurigo nodularis with topical capsaicin.

Authors:  S Ständer; T Luger; D Metze
Journal:  J Am Acad Dermatol       Date:  2001-03       Impact factor: 11.527

2.  Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus.

Authors:  Ayalew Tefferi; Rafael Fonseca
Journal:  Blood       Date:  2002-04-01       Impact factor: 22.113

3.  Efficacy of gabapentin in the management of pruritus of unknown origin.

Authors:  P D Yesudian; N J E Wilson
Journal:  Arch Dermatol       Date:  2005-12

Review 4.  [Diagnostic and therapeutic procedures in chronic pruritus].

Authors:  Sonja Ständer; Markus Streit; Ulf Darsow; Volker Niemeier; Maria Vogelgsang; Hartmut Ständer; Uwe Gieler; Harald Gollnick; Dieter Metze; Elke Weisshaar
Journal:  J Dtsch Dermatol Ges       Date:  2006-04       Impact factor: 5.584

5.  Connubial contact sensitization to clotrimazole.

Authors:  R Valsecchi; B Pansera; A di Landro; T Cainelli
Journal:  Contact Dermatitis       Date:  1994-04       Impact factor: 6.600

6.  [Topical administration of capsaicin in dermatology for treatment of itching and pain].

Authors:  S Reimann; T Luger; D Metze
Journal:  Hautarzt       Date:  2000-03       Impact factor: 0.751

7.  Inhibitory effect of loratadine on leukotriene B4 production by neutrophils either alone or during interaction with human airway epithelial cells.

Authors:  C Amsellem; W Czarlewski; M Lagarde; Y Pachéco
Journal:  Pulm Pharmacol Ther       Date:  1998       Impact factor: 3.410

8.  [Antipruritic effects of pimecrolimus and tacrolimus].

Authors:  S Ständer; T A Luger
Journal:  Hautarzt       Date:  2003-03-21       Impact factor: 0.751

9.  Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial.

Authors:  Ali Ihsan Gunal; Goksel Ozalp; Tahir Kurtulus Yoldas; Servin Yesil Gunal; Ercan Kirciman; Huseyin Celiker
Journal:  Nephrol Dial Transplant       Date:  2004-12       Impact factor: 5.992

10.  Pentoxifylline in the treatment of actinic prurigo. A preliminary report of 10 patients.

Authors:  Bertha Torres-Alvarez; Juan Pablo Castanedo-Cazares; Benjamin Moncada
Journal:  Dermatology       Date:  2004       Impact factor: 5.366

View more
  2 in total

Review 1.  [Chronic pruritus: principals of diagnostics and therapy].

Authors:  S Ständer
Journal:  Hautarzt       Date:  2007-07       Impact factor: 0.751

Review 2.  [Pruritus and dryness of the skin in chronic kidney insufficiency and dialysis patients - a review].

Authors:  Ulrike Durrant-Finn; Bernd Osten; Claudia Mügge; Pietro Nenoff
Journal:  Wien Med Wochenschr       Date:  2009
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.